RAPT Therapeutics Inc - Ordinary Shares

The momentum for this stock is not very good. RAPT Therapeutics Inc - Ordinary Shares is not a good value stock. RAPT Therapeutics Inc - Ordinary Shares is not very popular among insiders. Tradey thinks it is not wise to invest in RAPT Therapeutics Inc - Ordinary Shares.
Log in to see more information.
RAPT Fundamental Data by TradingView

News

RAPT Therapeutics (NASDAQ:RAPT) Given New $2.00 Price Target at UBS Group
RAPT Therapeutics (NASDAQ:RAPT) Given New $2.00 Price Target at UBS Group

Ticker Report RAPT Therapeutics (NASDAQ:RAPT - Free Report) had its target price lowered by UBS Group from $10.00 to $2.00 in a research note issued to investors on Monday morning, Benzinga reports. The brokerage...\n more…

Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $21.57
Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $21.57

Ticker Report RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned a consensus rating of "Hold" from the eleven research firms that are covering the company, MarketBeat Ratings reports. Nine...\n more…

Q3 2024 EPS Estimates for RAPT Therapeutics, Inc. (NASDAQ:RAPT) Boosted by Analyst
Q3 2024 EPS Estimates for RAPT Therapeutics, Inc. (NASDAQ:RAPT) Boosted by Analyst

Ticker Report RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Analysts at HC Wainwright raised their Q3 2024 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a report released on...\n more…

RAPT Therapeutics (NASDAQ:RAPT) Given "Neutral" Rating at HC Wainwright
RAPT Therapeutics (NASDAQ:RAPT) Given "Neutral" Rating at HC Wainwright

Ticker Report HC Wainwright reiterated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT - Free Report) in a research report released on Tuesday, Benzinga reports. Other equities analysts have also...\n more…

Rapt Therapeutics price target lowered by $7 at Wells Fargo, here's why
Rapt Therapeutics price target lowered by $7 at Wells Fargo, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $24.67 Consensus PT from Analysts
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $24.67 Consensus PT from Analysts

Ticker Report RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned a consensus rating of "Hold" from the twelve ratings firms that are presently covering the company, MarketBeat.com reports...\n more…